Guardant Health is a leading precision oncology company focused on helping conquer cancerglobally through use of its proprietary tests, vast data sets and advanced analytics.
Theoncology platform leverages capabilities to drive commercial adoption, improve patient clinicaloutcomes and lower healthcare costs across all stages of the cancer care continuum.

Bio-Rad is a global leader for life science research and clinical diagnostics that advance several applications for liquid biopsy. For assessing cfDNA and ctDNA in liquid biopsies, Droplet Digital PCR (ddPCR) offers unrivaled detection, precision, and absolute quantification. Celselect
Slide™ Technology with the Genesis System enables CTC enrichment and enumeration applications.

Yuanbin Chen, MD, PhD, MS, is Director of Thoracic Oncology and Melanoma Research and Vice President for Phase II/III Clinical Research at Cancer & Hematology Centers of Western Michigan in Grand Rapids, Michigan. In addition, he is Clinical Assistant Professor at Michigan State University College of Medicine in East Lansing. His primary clinical interests are thoracic oncology, melanoma, non-small cell lung cancer, and small cell lung cancer. Dr Chen earned his medical degree and master’s degree in pharmacology from Sun Yat-Sen University of Medical Sciences in Guangzhou, China, and his doctorate in molecular biology from Loyola University Chicago Medical Center in Maywood, Illinois. He completed his residency in internal medicine at Montefiore Medical Center, New York Medical College in Bronx, New York, and his fellowship in medical oncology at the National Institutes of Health/National Cancer Institute in Bethesda, Maryland. Dr Chen is a member of the American Society of Clinical Oncology, the American Society for Cancer Research and the International Association for the Study of Lung Cancer.

Menarini Silicon Biosystems offers the new CELLSEARCH® Circulating Multiple Myeloma Cell (CMMC) Enumeration assay, the first-of-its-kind LDT, which directly measures levels of plasma cells in peripheral blood. The CELLSEARCH® CMMC enumeration test provides new, complementary information to that of the bone marrow biopsy and other standard-of-care measures. Due to its minimally invasive nature, the test serially monitors plasma cell burden over time without requiring repeated bone marrow biopsies. Through our groundbreaking technology platforms and global lab services, we have standardized serial monitoring through cell-based liquid biopsy for a variety of conditions.

Dr. Marcello Stanzione is a Postdoctoral Fellow at Massachusetts General Hospital – Cancer Center working in the laboratory of Dr. Nick Dyson. His research interests are focused on molecular mechanisms of acquired resistance to chemotherapy and DNA damage response pathways in cancer cells. He is studying the cellular responses to DNA damage induced by the chemotherapy and comparing damage induction, repair and tolerance in mouse xenograft models derived from Small Cell Lung Cancer patients before and after relapse. During his PhD at Max Planck Institute of Molecular Cell Biology and Genetics, Dresden Germany, Dr. Stanzione discovered the function and the spatiotemporal regulation of a novel protein essential for meiotic homologous recombination and crossover formation in mammals.

I am an Instructor in the Dr. Kwok-Kin Wong’s laboratory at Perlmutter Cancer Center of NYU Langone Health. I have been leading the efforts to establish new murine models for oncoimmunology studies in lung cancer, as well as studying the role of cyclin dependent kinases (CDKs) in immunity. My main research focus is to utilize these immunocompetent murine models to study the immune tumor microenvironment (TME), to identify targets to enhance immunotherapy and to dissect the underlying mechanism leading to immune evasion, particularly in the field of small cell lung cancer (SCLC). My work in SCLC aims to improve our knowledge of dysregulated immune milieu and to provide a rationale for new combination regimens in patients.

Hiroyuki Yasuda is an associate professor at Keio University, School of Medicine, Tokyo, Japan. He has focused on translational research in lung cancer field. Selected Publications: 1. Ishioka K, Yasuda H*, ….., Fukunaga K. Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer. Cancer Res. 81(14):3916-3929, 2021. 2. Kawasaki K, ……., Yasuda H, …….. Sato T. An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping. Cell. 183(5):1420-1435.e21, 2020. 3. Ikemura S, Yasuda H*, ………, Soejima K. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc Natl Acad Sci U S A. 116(20):10025-10030. 2019. 4. Yasuda H, …….Eck MJ, Kobayashi SS, Costa DB. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 5(216):216ra177. 2013. 5. Yasuda H, Kobayashi S, Costa DB. EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications. Lancet Oncol. 13(1):e23-31. 2012. * Corresponding author

Katie Maher joins the IASLC as its Member Experience Coordinator. A graduate of Colorado State University in Business Administration, Katie has a wide array of diverse experience in marketing, content creation, customer service and event planning. And as part of the Member Experience team, Katie will provide incredible support to our members, meeting attendees, partners and other stakeholders.